Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA accepts IND for Ziopharm product

Feb. 6, 2012

Alpharadin available through new expanded access program

Feb. 6, 2012

Phase II trial assesses RO-4929097 in prostate cancer

Feb. 6, 2012

OGX-427 shows signs of efficacy in phase II trial

Feb. 6, 2012

Merck KGaA claims new ALK5 inhibitors

Feb. 6, 2012

Brazilian university patents new products with anticancer potential

Feb. 6, 2012

FDA grants orphan drug status to Del Mar Pharmaceuticals product

Feb. 6, 2012

Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer

Feb. 6, 2012

Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial

Feb. 6, 2012

Threshold Pharmaceuticals and Merck KGaA enter global agreement for hypoxia-targeted TH-302

Feb. 3, 2012

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...